{
    "xml": "<topic id=\"PHP81594\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/aclasta\" basename=\"aclasta\" title=\"Aclasta\">\n<title>Aclasta<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP82220\" outputclass=\"indicationsAndDose\" rev=\"1.29\" parent=\"/clinical-medicinal-product-information/aclasta\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of Paget's disease of bone</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;mg 1&#8239;times yearly, to be administered over at least 15&#8239;minutes, at least 500&#8239;mg elemental calcium twice daily (with vitamin D) for at least 10 days is recommended following infusion.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of postmenopausal osteoporosis and osteoporosis in men (including corticosteroid-induced osteoporosis)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;mg 1&#8239;times yearly, to be administered over at least 15&#8239;minutes, in patients with a recent low-trauma hip fracture, the dose should be given 2 or more weeks following hip fracture repair; before first infusion give 50000&#8211;125000&#8239;units of vitamin D.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP82262\" outputclass=\"nationalFunding\" rev=\"1.9\" parent=\"/clinical-medicinal-product-information/aclasta\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (February 2008) that in postmenopausal women <i>Aclasta</i>\n<tm tmtype=\"reg\"/> is accepted for restricted use within the NHS Scotland for the treatment of osteoporosis in those for whom oral treatment options for osteoporosis are inappropriate and when initiated by a specialist.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81594",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/aclasta",
    "basename": "aclasta",
    "title": "Aclasta",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of Paget's disease of bone",
                        "html": "Treatment of Paget's disease of bone"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "5 mg 1 times yearly, to be administered over at least 15 minutes, at least 500 mg elemental calcium twice daily (with vitamin D) for at least 10 days is recommended following infusion.",
                        "html": "<p>5&#8239;mg 1&#8239;times yearly, to be administered over at least 15&#8239;minutes, at least 500&#8239;mg elemental calcium twice daily (with vitamin D) for at least 10 days is recommended following infusion.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of postmenopausal osteoporosis and osteoporosis in men (including corticosteroid-induced osteoporosis)",
                        "html": "Treatment of postmenopausal osteoporosis and osteoporosis in men (including corticosteroid-induced osteoporosis)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "5 mg 1 times yearly, to be administered over at least 15 minutes, in patients with a recent low-trauma hip fracture, the dose should be given 2 or more weeks following hip fracture repair; before first infusion give 50000&#8211;125000 units of vitamin D.",
                        "html": "<p>5&#8239;mg 1&#8239;times yearly, to be administered over at least 15&#8239;minutes, in patients with a recent low-trauma hip fracture, the dose should be given 2 or more weeks following hip fracture repair; before first infusion give 50000&#8211;125000&#8239;units of vitamin D.</p>"
                    }
                ]
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (February 2008) that in postmenopausal women Aclasta is accepted for restricted use within the NHS Scotland for the treatment of osteoporosis in those for whom oral treatment options for osteoporosis are inappropriate and when initiated by a specialist.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (February 2008) that in postmenopausal women <i>Aclasta</i> <tm tmtype=\"reg\"/> is accepted for restricted use within the NHS Scotland for the treatment of osteoporosis in those for whom oral treatment options for osteoporosis are inappropriate and when initiated by a specialist.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}